Here for Your Patients, for Life.
NITYR helps simplify treatment at all life’s stages, liberating your patients from medication restrictions and putting their needs first, now and in the future.
Why NITYR?
Room temperature stable
- Does not require refrigeration
Easy to give. Easy to take.
- Very small, baby aspirin-sized tablets1
- Tasteless
- Can be administered to infants via oral syringe, crushed and mixed with applesauce, or swallowed whole
- Once-daily dosing is available for qualified patients*
No mealtime restrictions
NITYR is the only nitisinone tablet which can be taken with or without food
Support every step of the way
- 30-Day Free NITYR Program**
- Patient Liaison Support
- Clinical Metabolic Support
People who choose NITYR don’t look back
100% of fully enrolled, insured patients with Hereditary Tyrosinemia Type 1 who have received NITYR have not voluntarily returned to Orfadin§2
100% of the newborn babies prescribed NITYR had their medication shipped within 24 hours, since launch3
Easy to Give. Easy to Take.
Designed with your patients in mind, NITYR has flexible administration options to suit patients’ changing needs
Each NITYR Tablet is 20% of the volume of a single Orfadin§ (nitisinone) capsule1
The baby aspirin-size of NITYR may make it easier for toddlers to transition to swallowing their medication by themselves
When you prescribe NITYR, you’re in good company
Since 2017...
MOST of the top institutions prescribing NTBC choose NITYR for their patients with HT-14
The Top 2 children’s hospitals in the US chose NITYR for their patients with HT-15
NITYR has the same active ingredient your patients may already be taking, nitisinone (NTBC).
NITYR is bioequivalent to Orfadin§ (nitisinone) capsules with the:
- Same efficacy
- Same safety
- Same side effects, and may offer greater convenience6
The recommended dose of NITYR and Orfadin§ in the pediatric and adult population is 0.5 mg/kg administered orally twice daily.
Once daily dosing: NITYR can be prescribed once daily for patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone
Graph demonstrating Orfadin§ 10 mg arithmetic mean compared to NITYR 10 mg arithmetic mean, showing bioequivalence6
Drug product stability – accelerated conditions 40°C, 75% Relative Humidity7
The room-temperature stability of NITYR tablets allows for excursions between 59° F and 86° F (15° C and 30° C) without exceeding impurity limits set by the FDA.
- NITYR Tablets are available in 2 mg, 5 mg and 10 mg strengths
*For patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone.
**30-Day Free NITYR Program: Patients can try NITYR for 30 days, one time, for free, as long as their doctor prescribes it. Subject to terms and conditions, eligibility criteria, and other federal and state law. Terms and Conditions criteria are available at www.nityr.us/offerstcs.
§Orfadin is a registered trademark, licensed by Swedish Orphan Biovitrum AB (publ) and is marketed by Sobi, Inc.
References: 1. Data on file: NIT/03/18. 2. Data on file: NIT/03/21. Data represents fully enrolled, insured NITYR patients in the US from August 2017 to February 2021 3. Data on file: NIT/03/21. US patient data from August 2017 to February 2021. 4. Data on file: NIT/03/21. US patient data from August 2017 to February 2021. Institutions ranked by Definitive Healthcare data. 5. Data on file: NIT/03/21. US patient data from August 2017 to February 2021. Institutions ranked by U.S. News: Best Children’s Hospitals 2020-21. 6. Data on file: NIT/02/20. 7. Data on file: NIT/01/20